180 related articles for article (PubMed ID: 25791770)
21. [Autoimmune blistering skin diseases: recent advances].
Joly P
Presse Med; 2010 Oct; 39(10):1040-1. PubMed ID: 20692800
[No Abstract] [Full Text] [Related]
22. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
23. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
24. [Review of the current use of rituximab during 4 years in a French university hospital].
Reynaud Q; Killian M; Robles A; Mounsef F; Camdessanché JP; Mariat C; Cathébras P
Rev Med Interne; 2015 Dec; 36(12):800-12. PubMed ID: 26318843
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
27. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the treatment of autoimmune mucocutaneous blistering diseases.
Ahmed AR
Int J Periodontics Restorative Dent; 2007 Aug; 27(4):309-10. PubMed ID: 17726986
[No Abstract] [Full Text] [Related]
29. [Rituximab: a original biotherapy in auto-immune disorders].
Sibilia J; Sordet C
Rev Med Interne; 2005 Jun; 26(6):485-500. PubMed ID: 15936477
[TBL] [Abstract][Full Text] [Related]
30. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
32. B-cell-directed therapy for inflammatory skin diseases.
Nagel A; Hertl M; Eming R
J Invest Dermatol; 2009 Feb; 129(2):289-301. PubMed ID: 19148218
[TBL] [Abstract][Full Text] [Related]
33. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
34. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
35. Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic Neuropathy.
Sasaki S; Asahara D; Kaneko K; Komatsumoto S
Am J Case Rep; 2015 Jun; 16():357-60. PubMed ID: 26057570
[TBL] [Abstract][Full Text] [Related]
36. [RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER].
Mimouni D; Baum S
Harefuah; 2020 Jan; 159(1):31-33. PubMed ID: 31930805
[TBL] [Abstract][Full Text] [Related]
37. The need for markers and predictors of Rituximab treatment resistance.
Sitaru C; Thiel J
Exp Dermatol; 2014 Apr; 23(4):236-7. PubMed ID: 24450995
[TBL] [Abstract][Full Text] [Related]
38. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study.
Mahmoudi H; Farid AS; Nili A; Dayani D; Tavakolpour S; Soori T; Teimourpour A; Isazade A; Abedini R; Balighi K; Daneshpazhooh M;
J Am Acad Dermatol; 2021 Apr; 84(4):1098-1100. PubMed ID: 33359593
[No Abstract] [Full Text] [Related]
40. Rituximab in primary membranous nephropathy: first-line therapy, why not?
Cravedi P; Remuzzi G; Ruggenenti P
Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
